AI is spitting out more potential drugs than ever. This start-up wants to figure out which ones matter.

AI-driven drug discovery is creating a critical bottleneck: while AI models rapidly generate drug candidates, biopharma companies lack the infrastructure to efficiently characterize and validate them at scale. 10x Science addresses this enterprise pain point by combining AI with mass spectrometry analysis to automate molecular characterization, creating a recurring SaaS revenue model that pharma companies will depend on monthly regardless of individual drug outcomes. For IT leaders, this signals the emergence of domain-specific AI platforms that solve real operational constraints in regulated industries, creating opportunities to partner with biotech clients and build integration capabilities around AI-driven scientific workflows.